Case of multi-drug resistant (MDR) rapid progressor
18 April 2005. Related: Conference reports, Basic science and immunology.
Conference reports
Case report of antibody reversion and negative viral load four-years after treatment discontinuation
18 April 2005. Related: Conference reports, Basic science and immunology.
24-week efficacy of TMC114 in PI-experienced patients
18 April 2005. Related: Conference reports, Antiretrovirals.
Maturation inhibitor shows anti-HIV activity in single dose pilot study
18 April 2005. Related: Conference reports, Antiretrovirals.
New antiretrovirals at 12th CROI
18 April 2005. Related: Conference reports, Antiretrovirals.
Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age
18 April 2005. Related: Conference reports, Side effects.
Omega-3 supplement effective to reduce triglycerides
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Entecavir is effective against 3TC-resistant hepatitis B
18 April 2005. Related: Conference reports, Hepatitis coinfection.
Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Tenofovir is non-inferior to adefovir for the treatment of hepatitis B in HBV-HIV co-infected patients
18 April 2005. Related: Conference reports, Hepatitis coinfection.
7th International Congress on Drug Therapy in HIV Infection (ICDTHI), 14-18 November 2004, Glasgow
29 March 2005. Related: Conference reports.
Nandrolone decanoate combats HIV-related weight loss: results from three randomised studies
29 March 2005. Related: Conference reports, Coinfections and complications.
Atazanavir boosts intracellular saquinavir levels: data on important new dual-boosted regimen
29 March 2005. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Marked variability in plasma atazanavir levels: importance of ritonavir boosting and TDM
29 March 2005. Related: Conference reports, Antiretrovirals.
Effective switching to atazanavir/ritonavir in clinical practice
29 March 2005. Related: Conference reports, Antiretrovirals.
Ritonavir boosting may not overcome interaction between atazanavir and nevirapine
29 March 2005. Related: Conference reports, Antiretrovirals.
Nevirapine associated adverse events in a cohort of pregnant women
29 March 2005. Related: Conference reports, Pregnancy.
Higher nevirapine doses for children leads to better outcome
29 March 2005. Related: Conference reports, Paediatric care.
TDM in Ugandan study highlights importance of refridgerated ritonavir
29 March 2005. Related: Conference reports, Antiretrovirals.
Responses to TB treatment in HIV positive and HIV negative patients in the UK
29 March 2005. Related: Conference reports, TB coinfection.
800mg efavirenz may not be needed with rifampicin-based TB regimens, especially in African patients
29 March 2005. Related: Conference reports, TB coinfection.
EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects
29 March 2005. Related: Conference reports, Side effects.
Lower d4T dose maintains virologic suppression and CD4 increases
29 March 2005. Related: Conference reports, Antiretrovirals.
6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (IWADRLH) 26-28 October 2004, Washington
31 January 2005. Related: Conference reports.
Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Nucleosides reduce PPAR-gamma: a role for rosiglitazone without thymidine analogues?
31 January 2005. Related: Conference reports.
Potential for uridine to treat mitochondrial toxicity: still only in vitro data
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’
31 January 2005. Related: Conference reports, Antiretrovirals.
rHGH reduces central fat accumulation in adolescent lipodystrophy
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Weight loss is associated with elevated PBMC proviral DNA levels
31 January 2005. Related: Conference reports, Basic science and immunology.
Coronary artery bypass graft is safe in HIV-positive patients but shows higher risk of longer term events
31 January 2005. Related: Conference reports, Other news.
Endothelial dysfunction similar in ARV-experienced and -naive patients
31 January 2005. Related: Conference reports, Side effects.
Pravastatin improves lipid profiles but not endothelial function
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Indinavir impairs endothelial function without insulin resistance
31 January 2005. Related: Conference reports, Antiretrovirals.
Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Improvement of lipids following switch to tenofovir
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
HCV coinfection linked to discontinuing ART due to toxicity
31 January 2005. Related: Conference reports, Hepatitis coinfection.
Restorative treatments for HIV-associated lipoatrophy
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington
31 January 2005. Related: Conference reports.
Tipranavir in treatment experienced patients: results from RESIST-1
31 January 2005. Related: Conference reports, Antiretrovirals.
Reverset: first data in patients with nucleoside resistance
31 January 2005. Related: Conference reports, Antiretrovirals.
Poor response with tenofovir and ddI backbone causes early study termination
31 January 2005. Related: Conference reports, Antiretrovirals.
Paradoxical CD4 response with tenofovir and ddI backbone
29 January 2005. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy
29 January 2005. Related: Conference reports, Antiretrovirals.
Limited stability of lopinavir/r (Kaletra) above 25°C
29 January 2005. Related: Conference reports, Antiretrovirals.
Atorvastatin requires dose reduction with tipranavir/r
29 January 2005. Related: Conference reports, PK and drug interactions.
Once-daily T-20 is less effective than twice daily: lower potency is related to C trough
29 January 2005. Related: Conference reports, Antiretrovirals.
Further genetic link to efavirenz absorption
29 January 2005. Related: Conference reports, Antiretrovirals.
Long-term response to FTC in children is similar to adults
29 January 2005. Related: Conference reports, Paediatric care.
Side effects update: hypersensitivity, heart, bones
29 January 2005. Related: Conference reports, Side effects.
XV International World AIDS Conference, 11-16 July 2004, Bangkok
6 November 2004. Related: Conference reports.
Women and HIV: research directions
6 November 2004. Related: Conference reports, Women's health.
The X4 files: sampling the science on HIV co-receptors in Bangkok
6 November 2004. Related: Conference reports, Antiretrovirals.
10th BHIVA Autumn Conference 8-9 October 2004, London
6 November 2004. Related: Conference reports.
BHIVA audit on management of HIV/Hepatitis coinfection
6 November 2004. Related: Conference reports, Hepatitis coinfection.
XV International World AIDS Conference, 11-16 July 2004, Bangkok
6 September 2004. Related: Conference reports.
Dollars, commerce, politics and prejudice all present obstacles to scaling up access to treatment in resource poor countries
6 September 2004. Related: Conference reports, Treatment access.
MTCT programmes in South Africa: nevirapine and the minister
6 September 2004. Related: Conference reports, Treatment access, Pregnancy.
Urgency of global access to ARV treatment for IV drug users
6 September 2004. Related: Conference reports, Treatment access, Injecting drug users.
Replace myths with evidence–based policies on IV drug use
6 September 2004. Related: Conference reports, Treatment access, Injecting drug users.
Adding Combivir to single dose nevirapine for reduction of MTCT significantly reduces resistance
6 September 2004. Related: Conference reports, Pregnancy.
Lopinavir/r levels reduced during pregnancy
6 September 2004. Related: Conference reports, Pregnancy.
Another chance for 3TC in patients with M184V mutation?
6 September 2004. Related: Conference reports, Antiretrovirals, Treatment strategies, Drug resistance.
Kaletra monotherapy: small studies and early data
6 September 2004. Related: Conference reports, Antiretrovirals, Treatment strategies.